ORG Partners LLC Decreases Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

ORG Partners LLC trimmed its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 293 shares of the medical equipment provider’s stock after selling 23 shares during the quarter. ORG Partners LLC’s holdings in Intuitive Surgical were worth $144,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently modified their holdings of ISRG. Capital Research Global Investors acquired a new position in shares of Intuitive Surgical during the 1st quarter worth approximately $374,390,000. Vanguard Group Inc. lifted its position in Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after buying an additional 493,126 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Intuitive Surgical by 51.2% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after purchasing an additional 302,382 shares during the last quarter. Strategic Financial Concepts LLC boosted its holdings in Intuitive Surgical by 40,221.4% in the 2nd quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock valued at $1,184,000 after purchasing an additional 265,461 shares during the last quarter. Finally, GQG Partners LLC acquired a new stake in shares of Intuitive Surgical during the 1st quarter worth approximately $99,523,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

NASDAQ ISRG opened at $478.47 on Wednesday. The firm’s fifty day moving average price is $481.94 and its 200 day moving average price is $436.37. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $496.48. The company has a market capitalization of $169.71 billion, a price-to-earnings ratio of 86.37, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the company posted $1.18 earnings per share. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the transaction, the director now directly owns 821 shares in the company, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Intuitive Surgical news, EVP Robert Desantis sold 1,413 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $438.60, for a total transaction of $619,741.80. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,414,931.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $490.28, for a total value of $220,626.00. Following the completion of the transaction, the director now owns 821 shares in the company, valued at $402,519.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock valued at $25,528,753 over the last quarter. Company insiders own 0.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ISRG. JPMorgan Chase & Co. increased their price objective on Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Truist Financial increased their target price on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a research note on Monday. Morgan Stanley boosted their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the company an “equal weight” rating in a research note on Monday, July 15th. Stifel Nicolaus increased their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research report on Friday, July 19th. Finally, Royal Bank of Canada boosted their target price on Intuitive Surgical from $515.00 to $525.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and an average target price of $467.55.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.